Arbutus Biopharma (ABUS) Total Debt (2016 - 2017)

Arbutus Biopharma (ABUS) posted quarterly Total Debt of $12.0 million for Q4 2017, little changed year-on-year from $12.0 million in Q4 2016, and little changed on a QoQ basis from $12.0 million in Q3 2017.

Arbutus Biopharma (ABUS) Total Debt (2016 - 2017) Analysis & Trends

Arbutus Biopharma (ABUS) has reported Total Debt for 2 consecutive years, with $12.0 million the latest figure, recorded in Q4 2017.

  • Quarterly Total Debt changed 0.0% year-over-year to $12.0 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $12.0 million (changed 0.0% YoY) and the FY2017 annual result came in at $12.0 million, changed 0.0% from the prior year.
  • Total Debt was little changed at $12.0 million in Q4 2017 per ABUS's latest filing, from $12.0 million in the prior quarter.
  • Over the last five years, Total Debt for ABUS reached as high as $12.0 million in Q4 2016 and fell as low as $12.0 million in Q4 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.96 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 959.06 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Arbutus Biopharma 880.36 Mn 785.13 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2017 12.00 Mn
Sep 30, 2017 12.00 Mn
Jun 30, 2017 12.00 Mn
Mar 31, 2017 12.00 Mn
Dec 31, 2016 12.00 Mn